Last reviewed · How we verify
Adjuvant, non-live RSV vaccine
Adjuvant, non-live RSV vaccine is a Vaccine Biologic drug developed by University Health Network, Toronto. It is currently in Phase 3 development for RSV infection prevention in adults (Phase 3). Also known as: Arexvy.
An adjuvanted non-live RSV vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus without containing live virus.
An adjuvanted non-live RSV vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus without containing live virus. Used for RSV infection prevention in adults (Phase 3).
At a glance
| Generic name | Adjuvant, non-live RSV vaccine |
|---|---|
| Also known as | Arexvy |
| Sponsor | University Health Network, Toronto |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or recombinant RSV antigens combined with an adjuvant to enhance immune response. The adjuvant amplifies the body's innate immune activation, promoting stronger and more durable antibody production and T-cell responses against RSV. This approach aims to provide protection against RSV infection while avoiding the safety concerns associated with live attenuated vaccines.
Approved indications
- RSV infection prevention in adults (Phase 3)
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- RSV Vaccine in Transplant Recipients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant, non-live RSV vaccine CI brief — competitive landscape report
- Adjuvant, non-live RSV vaccine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Adjuvant, non-live RSV vaccine
What is Adjuvant, non-live RSV vaccine?
How does Adjuvant, non-live RSV vaccine work?
What is Adjuvant, non-live RSV vaccine used for?
Who makes Adjuvant, non-live RSV vaccine?
Is Adjuvant, non-live RSV vaccine also known as anything else?
What drug class is Adjuvant, non-live RSV vaccine in?
What development phase is Adjuvant, non-live RSV vaccine in?
What are the side effects of Adjuvant, non-live RSV vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: University Health Network, Toronto — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for RSV infection prevention in adults (Phase 3)
- Also known as: Arexvy
- Compare: Adjuvant, non-live RSV vaccine vs similar drugs
- Pricing: Adjuvant, non-live RSV vaccine cost, discount & access